CD3
11 drugs MetabolicOncology
3
approved indications
11
Approved Drugs
8
Companies
8
Indications
2
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (8 companies)
✓ All 11 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (8 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
Roche 2 drugs
Johnson & Johnson 2 drugs
Amgen 2 drugs
By Therapeutic Area
Oncology 9 drugs
Metabolic 1 drugs
By Therapeutic Area
Oncology 9 drugs
EPKINLY, COLUMVI, TALVEY, ELREXFIO +5 more
Metabolic 1 drugs
TZIELD
Other 1 drugs
KIMMTRAK
Indications Treated
Type 1 DiabetesDiffuse Large B-Cell LymphomaFollicular LymphomaHigh-Grade B-Cell LymphomaUveal MelanomaMultiple MyelomaAcute Lymphoblastic LeukemiaSmall Cell Lung Cancer
All Drugs Targeting CD3
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| EPKINLY | GENMAB US, INC. | 2023 | 3 | Oncology |
| COLUMVI | Roche | 2023 | 2 | Oncology |
| TZIELD | PROVENTION BIO INC | 2022 | 1 | Metabolic |
| KIMMTRAK | IMMUNOCORE LTD | 2022 | 1 | |
| TALVEY | Johnson & Johnson | 2023 | 1 | Oncology |
| ELREXFIO | Pfizer | 2023 | 1 | Oncology |
| BLINCYTO | Amgen | 2014 | 1 | Oncology |
| LYNOZYFIC | RENGENERON PHARMACEUTICALS, INC. | 2025 | 1 | Oncology |
| TECVAYLI | Johnson & Johnson | 2022 | 1 | Oncology |
| IMDELLTRA | Amgen | 2024 | 1 | Oncology |
| LUNSUMIO | Roche | 2022 | 1 | Oncology |